HLS Therapeutics Inc
TSX:HLS
Net Margin
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Peer Comparison
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| CA |
|
HLS Therapeutics Inc
TSX:HLS
|
140.7m CAD |
Loading...
|
|
| US |
|
Mckesson Corp
NYSE:MCK
|
117.6B USD |
Loading...
|
|
| US |
|
Cencora Inc
NYSE:COR
|
69.7B USD |
Loading...
|
|
| US |
A
|
Amerisourcebergen Corp
LSE:0HF3
|
69.5B USD |
Loading...
|
|
| US |
|
Cardinal Health Inc
NYSE:CAH
|
53.7B USD |
Loading...
|
|
| AU |
|
Sigma Healthcare Ltd
ASX:SIG
|
35.9B AUD |
Loading...
|
|
| US |
|
Henry Schein Inc
NASDAQ:HSIC
|
9.5B USD |
Loading...
|
|
| CN |
|
Shanghai Pharmaceuticals Holding Co Ltd
SSE:601607
|
64B CNY |
Loading...
|
|
| CN |
|
Huadong Medicine Co Ltd
SZSE:000963
|
63.8B CNY |
Loading...
|
|
| CN |
|
Sinopharm Group Co Ltd
HKEX:1099
|
65.6B HKD |
Loading...
|
|
| KR |
|
Celltrion Healthcare Co Ltd
KOSDAQ:091990
|
12.2T KRW |
Loading...
|
Market Distribution
| Min | -9 940 586.9% |
| 30th Percentile | -85.9% |
| Median | -7.8% |
| 70th Percentile | 5.5% |
| Max | 60 777.6% |
Other Profitability Ratios
HLS Therapeutics Inc
Glance View
HLS Therapeutics, Inc. operates as a pharmaceutical company. The company is headquartered in Etobicoke, Ontario and currently employs 92 full-time employees. The firm is focused on developing clinically differentiated pharmaceutical products in the specialty central nervous system (CNS) and cardiovascular (CV) markets. Its products include Vascepa, Trinomia, Clozaril, CSAN Pronto, PERSERIS and MyCare Psychiatry/MyCare Insite. Its lead product, Clozaril, is an atypical antipsychotic indicated in the management of symptoms of treatment-resistant schizophrenia for the Canadian and United States markets. CSAN Pronto is a capillary point-of-care medical device designed to enhance and simplify the mandatory safety blood monitoring process for patients that are prescribed Clozaril. Vascepa capsules reduce the risk of cardiovascular events, such as cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, coronary revascularization, or hospitalization for unstable angina in statin-treated patients with elevated triglycerides.
See Also
Net Margin is calculated by dividing the Net Income by the Revenue.
The current Net Margin for HLS Therapeutics Inc is -25.3%, which is above its 3-year median of -37.8%.
Over the last 3 years, HLS Therapeutics Inc’s Net Margin has increased from -34.7% to -25.3%. During this period, it reached a low of -45.8% on Mar 31, 2024 and a high of -25.3% on Oct 30, 2025.
